Spots Global Cancer Trial Database for A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Official Title: A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Study ID: NCT03145909
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-176 for participants with advanced solid tumors likely to express Prolactin Receptor (PRLR). The study will consist of 2 cohorts: Dose Escalation and Expanded Recommended Phase 2 Dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute - Pima /ID# 161078, Scottsdale, Arizona, United States
City of Hope /ID# 161079, Duarte, California, United States
Yale University /ID# 201357, New Haven, Connecticut, United States
St. Lukes Cancer Institute /ID# 201353, Kansas City, Missouri, United States
Washington University-School of Medicine /ID# 162745, Saint Louis, Missouri, United States
Rutgers Cancer Institute of NJ /ID# 161080, New Brunswick, New Jersey, United States
University of Utah /ID# 161606, Salt Lake City, Utah, United States
Sydney Children's Hospital /ID# 162917, Randwick, New South Wales, Australia
Mater Misericordiae /ID# 162918, South Brisbane, Queensland, Australia
Rigshospitalet /ID# 159707, Copenhagen Ø, Hovedstaden, Denmark
Hosp Univ Madrid Sanchinarro /ID# 161644, Madrid, , Spain
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
